Other Information
−Removed: During the period from April 1, 2023, to June 30, 2023, our executive officers and directors adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities as noted below:
+Added: During the period from July 1, 2023, to September 30, 2023, our executive officers and directors adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities as noted below:
Name and Title Action Date Trading Arrangement Total Shares Authorized
1 unchanged sentence
Rule 10b5-1* Non-Rule 10b5-1**
−Removed: Boyer Adopt 5/31/2023 X 11,590 2/15/2024
−Removed: (Chief Corporate Affairs Officer)
−Removed: Rastetter Adopt 5/31/2023 X 10,900 2/15/2024
−Removed: (Chair of the Board of Directors) plus the Additional Sell
−Removed: to Cover Shares
−Removed: (as defined in footnote 1)
+Added: Adopt 8/22/2023 X 167,858 1/12/2024
+Added: (Chief Executive Officer)
+Added: Adopt 8/24/2023 X 61,749 8/07/2024
+Added: (Chief Legal Officer)
______________
1 unchanged sentence
** Not intended to satisfy the affirmative defense of Rule 10b5-1(c)
−Removed: Rastetter’s plan provides for the exercise of a vested stock option to purchase 20,000 shares (the “Vested Option”) and the associated sale of 10,900 shares plus an additional number of shares as reasonably estimated by a brokerage firm such that the net proceeds from all shares sold are sufficient to cover the exercise cost and taxes associated with the exercise of the Vested Option (the “Additional Sell to Cover Shares”).
The following exhibits are filed as part of, or incorporated by reference into, this report:
4 unchanged sentences
Bylaws, as amended
+Added: Incorporated by reference to Exhibit 3.2 of the Company’s Quarterly Report on Form 10-Q filed on August 1, 2023
4.1 Description:
13 unchanged sentences
31.1 Description:
−Removed: Neurocrine Biosciences, Inc.
−Removed: 2020 Equity Incentive Plan, as amended and restated
−Removed: 31.1 Description:
Certification of Chief Executive Officer pursuant to Rules 13a-14 and 15d-14 promulgated under the Securities Exchange Act of 1934
20 unchanged sentences
______________
−Removed: + Management contract or compensatory plan or arrangement.
* These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C.
3 unchanged sentences
NEUROCRINE BIOSCIENCES, INC.
−Removed: August 1, 2023
+Added: October 31, 2023
/s/ Matthew C.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.